Exelixis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are eleven US patents protecting EXELIXIS drugs.
There are two hundred and seven patent family members on EXELIXIS drugs in thirty-two countries and nineteen supplementary protection certificates in sixteen countries.
Drugs and US Patents for Exelixis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | Yes | 11,091,440 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 8,497,284 | ⤷ Sign Up | ⤷ Sign Up | ||||
Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | Yes | 11,298,349 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | 10,034,873 | ⤷ Sign Up | ⤷ Sign Up | ||||
Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 8,877,776 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 2392564 | ⤷ Sign Up |
European Patent Office | 2409704 | ⤷ Sign Up |
Japan | 2021050233 | ⤷ Sign Up |
Hong Kong | 1164305 | ⤷ Sign Up |
Japan | 6513598 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2213661 | PA2014033,C2213661 | Lithuania | ⤷ Sign Up | PRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321 |
2213661 | 300678 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
2213661 | 132014902289810 | Italy | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB(COMETRIQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/890/001,002,003, 20140326 |
2213661 | 122014000091 | Germany | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321 |
2213661 | 220 50007-2014 | Slovakia | ⤷ Sign Up | PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.